The RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

The RNA‐binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma

Published:2020-11-24 Issue:2 Volume:15 Page:579-595
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Panzeri Valentina¹²^ORCID,Manni Isabella³^ORCID,Capone Alessia⁴^ORCID,Naro Chiara²⁵^ORCID,Sacconi Andrea⁶^ORCID,Di Agostino Silvia⁷^ORCID,Latouliere Luisa³^ORCID,Montori Andrea⁸^ORCID,Pilozzi Emanuela⁸^ORCID,Piaggio Giulia³^ORCID,Capurso Gabriele⁹^ORCID,Sette Claudio²⁴^ORCID

Affiliation:

1. Department of Science Medical/Chirurgic and Translational Medicine University of Rome “Sapienza” Italy

2. Department of Neuroscience Section of Human Anatomy Catholic University of the Sacred Heart Rome Italy

3. UOSD SAFU Department of Research, Diagnosis and Innovative Technologies IRCCS Regina Elena National Cancer Institute Rome Italy

4. Fondazione Santa Lucia IRCCS Rome Italy

5. IRCCS Fondazione Policlinico Agostino Gemelli Rome Italy

6. Clinical Trial Center, Biostatistics and Bioinformatics Unit IRCCS Regina Elena National Cancer Institute Rome Italy

7. Oncogenomic and Epigenetic Unit Department of Diagnostic Research and Technological Innovation IRCCS Regina Elena National Cancer Institute Rome Italy

8. Department of Clinical and Molecular Medicine UOC Anatomia Patologica Sant' Andrea Hospital Sapienza University of Rome Italy

9. PancreatoBiliary Endoscopy and EUS Division Pancreas Translational and Clinical Research Center San Raffaele Scientific Institute IRCCS Milan Italy

Funder

Università Cattolica del Sacro Cuore

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12847

Reference49 articles.

1. Cancer statistics, 2019

2. Therapeutic developments in pancreatic cancer: current and future perspectives

3. RNA splicing factors as oncoproteins and tumour suppressors

4. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MEX3A is a new diagnostic, independent prognostic biomarker and a promising therapeutic target in gliomas;2024-05-13

2. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer;Cell Reports Medicine;2024-02

3. MEX3A induces the development of thyroid cancer via targeting CREB1;Cell Biology International;2023-08-02

4. MEX3A determines in vivo hepatocellular carcinoma progression and induces resistance to sorafenib in a Hippo-dependent way;Hepatology International;2023-07-17

5. MiR-1258/MEX3A Axis Inhibits the Proliferation of Thyroid Cancer Cells and EMT by Inhibiting the AKT Pathway;J BIOL REG HOMEOS AG;2023